Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen · Immunity · 2020
Cited by 2,210 works. doi:10.1016/j.immuni.2019.12.011 Open-access PDF
Authors
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Signatures of mutational processes in human cancer
- Enhancement of Antitumor Immunity by CTLA-4 Blockade